MRPL35

Across TCGA pan-cancer cohorts, MRPL35 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL35 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL35 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL35 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where MRPL35 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	22	view →
LUAD	DFS	Quartile	All	0.383	1.000	.004	15	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.685	.017	10	view →
PDAC	OS	Median	III,IV	0.299	0.812	.023	6	view →
HNSC	DFS	Median	II,III,IV	0.760	0.555	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPL35–CCRCC (OS)

Open the CCRCC breakdown →